Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence

• Principais autores: Emir M. Muzurović MD, MM (Autor), Špela Volčanšek MD (Autor), Karin Zibar Tomšić MD, PhD (Autor), Andrej Janež MD, PhD (Autor), Dimitri P. Mikhailidis MD (Autor), Manfredi Rizzo MD, PhD (Autor), Christos S. Mantzoros MD (Autor)
• Formato: Livro
• Publicado em: SAGE Publishing, 2022-12-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

The obesity pandemic is accompanied by increased risk of developing metabolic syndrome (MetS) and related conditions: non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH), type 2 diabetes mellitus (T2DM) and cardiovascular (CV) disease (CVD). Lifestyle, as well as an imbala...